Thyrocare Technologies Announces Q1 FY27 Results; Reappoints Internal Auditor for 2026-27

Thyrocare Technologies Announces Q1 FY27 Results; Reappoints Internal Auditor for 2026-27​

Thyrocare Technologies Ltd has announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company's Board of Directors approved these results alongside a Limited Review Report prepared by Price Waterhouse Chartered Accountants LLP. Furthermore, the Board also sanctioned the re-appointment of M/s Ernst & Young LLP as Internal Auditors for the financial year 2026-27.

The unaudited standalone and consolidated results were reviewed and recommended by the Audit Committee before being approved by the Board on July 23, 2026. The statutory auditors have expressed an unmodified conclusion on both sets of results.

Financial Performance Highlights (Quarter ended June 30, 2026)​

The company maintained strong operational profitability in the quarter. Key performance indicators across the standalone and consolidated segments are summarized below:

Detailed Financial Outcomes​

Standalone Performance Overview​

For the quarter ended June 30, 2026, Thyrocare Technologies reported a significant financial outcome based on its standalone results. The company generated Total Revenue of 229.17 Crores. Expenses for the period stood at 162.54 Crores, leading to a Profit for the Period/Year of 50.17 Crores.

Consolidated Group Results​

The consolidated results reflected the performance of the Holding Company along with its subsidiaries, including Nuclear Healthcare Limited, Pulse Hitech Health Services (Ghatkopar) LLP, Think Health Diagnostic Private Limited, Thyrocare Laboratories (Tanzania) Limited, and Equinox Labs Private Limited. The consolidated entity achieved a Total Revenue of 244.17 Crores for the quarter.

Internal Audit and Management Updates​

The Board meeting addressed the reappointment of M/s Ernst & Young LLP, Chartered Accountants, as the Internal Auditors for the Financial Year 2026-27. The appointment was based on the recommendation of the Audit Committee.

Additionally, the company provided updates regarding employee stock options, noting that 3,733 equity stock options and zero equity stock options granted to employees were forfeited during the quarter due to the discontinuance of services of those employees. These forfeited options have been added back to the available pool.

THYROCARE Stock Price Movement​

Shares of Thyrocare Technologies Limited shed 2.41% today, settling at ₹545.25 as the equity closed in negative territory. The stock saw a wide trading range throughout the session, moving between a low of ₹541 and a high of ₹558.6, while logging total traded volume of 311,870 shares.